El Guerrab et al. (2016) also investigated the synergistic effect of the currently FDA-approved mABs cetuximab and panutimab and TKIs gefitinib and erlotinib in the EGFR-overexpressing breast cancer cell lines MDA-MB-468 and MDA-MB-231. The gene discussed is EGFR; the disease is breast cancer.